Company: NDRA
Filing Date: 2025-10-28
Form Type: DEF 14A
Source: 0001654954-25-012254
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-28
Form: DEF 14A
Chunk 5
---
 death, resignation, or removal); 
 the approval, on a non-binding, advisory basis, of executive compensation (“Say-on-Pay”);                                                                                                                                                                                             
 the ratification of the Audit Committee’s appointment of RBSM LLP (“RBSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;                                                                                               |
|:--|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| · | the approval of an amendment to our Certificate of Incorporation increasing the number of authorized shares of common stock from 20,000,000 shares to 1,000,000,000 shares (“Share Increase”);                                                                                        |
| · | the approval of an amendment to our Certificate of Incorporation to exculpate certain officers of the Company as permitted by recent changes to Delaware law (“Officer Exculpation”); and                                                                                             |
| · | the approval of an amendment to our 2016 Omnibus Incentive Plan (the “2016 Plan” and such amendment, the “2016 Plan Amendment”).                                                                                                                                                      |

The Board is not aware of any other matters to be brought before the 2025 Annual Meeting. If other matters are properly raised at the 2025 Annual Meeting, the proxy holders may vote any shares represented by proxy in their discretion.

What are the Board’s voting recommendations?

The Board recommends that you vote your shares:

| · | FOR the election of each of the four nominees named in this proxy statement to the Board;                                                                                       |
| · | FOR the approval of the advisory vote on executive compensation;                                                                                                                |
| · | FOR the ratification of the Audit Committee’s appointment of RBSM as the Company’s independent registered public accounting firm for 2025;                                      |
| · | FOR the approval of an amendment to our Certificate of Incorporation increasing the number of authorized shares of common stock from 20,000,000 shares to 1,000,000,000 shares; |
| · | FOR the approval of an amendment to our Certificate of Incorporation to exculpate certain officers of the Company as permitted by recent changes to Delaware law; and           |
| · | FOR the approval of the 2016 Plan Amendment.                                                                                                                                    |

How can I participate in the 2025 Annual Meeting?

You may attend the 2025 Annual Meeting in person solely by means of remote communication via live webcast at www.virtualshareholdermeeting.com/NDRA2025. The 2025 Annual Meeting will begin at